Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025)

Mesoblast (MESO) posted quarterly Non-Current Deffered Revenue of $2.5 million for Q4 2025, little changed year-on-year from $2.5 million in Q4 2024, and little changed on a QoQ basis from $2.5 million in Q2 2025.

Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends

Mesoblast (MESO) has reported Non-Current Deffered Revenue for 8 consecutive years, with $2.5 million the latest figure, recorded in Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.5 million, changed 0.0% from the prior year.
  • Non-Current Deffered Revenue steadied at $2.5 million in Q4 2025 per MESO's latest filing, from $2.5 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for MESO reached as high as $2.5 million in Q1 2021 and fell as low as $2.5 million in Q1 2021.
  • A 5-year average of $2.5 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Deffered Revenue.
  • The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • Year by year, Non-Current Deffered Revenue stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Mesoblast 2.08 Bn 1.95 Bn - 2.50 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 2.50 Mn
Jun 30, 2025 2.50 Mn
Dec 31, 2024 2.50 Mn
Jun 30, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
Jun 30, 2023 2.50 Mn
Mar 31, 2023 2.50 Mn
Dec 31, 2022 2.50 Mn
Sep 30, 2022 2.50 Mn
Jun 30, 2022 2.50 Mn
Mar 31, 2022 2.50 Mn
Dec 31, 2021 2.50 Mn
Sep 30, 2021 2.50 Mn
Jun 30, 2021 2.50 Mn
Mar 31, 2021 2.50 Mn
Dec 31, 2020 2.50 Mn
Sep 30, 2020 2.50 Mn
Jun 30, 2020 2.50 Mn
Mar 31, 2020 2.50 Mn
Dec 31, 2019 10.00 Mn